{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:59:10Z","timestamp":1788260350856,"version":"build-2803163510"},"reference-count":139,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Kazan Federal University for the state assignment in the sphere of scientific activities","doi-asserted-by":"publisher","award":["FZSM-2023-0011"],"award-info":[{"award-number":["FZSM-2023-0011"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Kazan Federal University for the state assignment in the sphere of scientific activities","doi-asserted-by":"publisher","award":["PRIORITY-2030"],"award-info":[{"award-number":["PRIORITY-2030"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kazan Federal University Strategic Academic Leadership Program","award":["FZSM-2023-0011"],"award-info":[{"award-number":["FZSM-2023-0011"]}]},{"name":"Kazan Federal University Strategic Academic Leadership Program","award":["PRIORITY-2030"],"award-info":[{"award-number":["PRIORITY-2030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Systemic autoimmune diseases (SAIDs), such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and rheumatoid arthritis (RA), are fully related to the unregulated innate and adaptive immune systems involved in their pathogenesis. They have similar pathogenic characteristics, including the interferon signature, loss of tolerance to self-nuclear antigens, and enhanced tissue damage like necrosis and fibrosis. Glucocorticoids and immunosuppressants, which have limited specificity and are prone to tolerance, are used as the first-line therapy. A plethora of novel immunotherapies have been developed, including monoclonal and bispecific antibodies, and other biological agents to target cellular and soluble factors involved in disease pathogenesis, such as B cells, co-stimulatory molecules, cytokines or their receptors, and signaling molecules. Many of these have shown encouraging results in clinical trials. CAR-T cell therapy is considered the most promising technique for curing autoimmune diseases, with recent successes in the treatment of SLE and SSc. Here, we overview novel therapeutic approaches based on CAR-T cells and antibodies for targeting systemic autoimmune diseases.<\/jats:p>","DOI":"10.3390\/antib13010010","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:44:08Z","timestamp":1706777048000},"page":"10","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies"],"prefix":"10.3390","volume":"13","author":[{"given":"Vitaly","family":"Chasov","sequence":"first","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zmievskaya","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ganeeva","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvina","family":"Gilyazova","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Davletshin","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3832-0805","authenticated-orcid":false,"given":"Marat","family":"Khaliulin","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-8190","authenticated-orcid":false,"given":"Emmanuel","family":"Kabwe","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-2942","authenticated-orcid":false,"given":"Yuriy","family":"Davidyuk","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aygul","family":"Valiullina","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9427-5739","authenticated-orcid":false,"given":"Albert","family":"Rizvanov","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"},{"name":"Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-0032","authenticated-orcid":false,"given":"Emil","family":"Bulatov","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"},{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human Autoimmune Diseases: A Comprehensive Update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105143","DOI":"10.1016\/j.jbspin.2021.105143","article-title":"Hydroxychloroquine in Systemic and Autoimmune Diseases: Where Are We Now?","volume":"88","author":"Dima","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/03009742.2017.1336570","article-title":"Relationship between Glucocorticoid Dose and Adverse Events in Systemic Lupus Erythematosus: Data from a Randomized Clinical Trial","volume":"47","author":"Emamikia","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: First Targeted Biological Treatment for Systemic Lupus Erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 Pipeline of Targeted Therapies under Clinical Development for Systemic Lupus Erythematosus: A Systematic Review of Trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal Antibodies as Immunomodulatory Therapy against Cancer and Autoimmune Diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","article-title":"Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date","volume":"34","author":"Zhao","year":"2020","journal-title":"BioDrugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11926-023-01115-8","article-title":"Possible Role of Dysbiosis of the Gut Microbiome in SLE","volume":"25","author":"Kalayci","year":"2023","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"799788","DOI":"10.3389\/fimmu.2021.799788","article-title":"Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies","volume":"12","author":"Pan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","unstructured":"Bergmann, C., M\u00fcller, F., J\u00f6rg, D., Gy\u00f6rfi, D.M.H., V\u00f6lkl, S., Aigner, M., Harrer, T., Bayerl, N., Atzinger, A., and Taubmann, J. (2023). Scientific Abstracts, European League Against Rheumatism."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ganeeva, I., Zmievskaya, E., Valiullina, A., Kudriaeva, A., Miftakhova, R., Rybalov, A., and Bulatov, E. (2022). Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies. Bioengineering, 9.","DOI":"10.3390\/bioengineering9120808"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.autrev.2014.10.003","article-title":"A Volcanic Explosion of Autoantibodies in Systemic Lupus Erythematosus: A Diversity of 180 Different Antibodies Found in SLE Patients","volume":"14","author":"Yaniv","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global Epidemiology of Systemic Lupus Erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539797","DOI":"10.3389\/fimmu.2020.539797","article-title":"A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and Pathogenesis of Systemic Lupus Erythematosus and Lupus Nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14712598.2016.1171840","article-title":"Recent Advances and Current State of Immunotherapy in Systemic Lupus Erythematosus","volume":"16","author":"Mok","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The Making of Bispecific Antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Robinson, R. (2006). Distinct B Cell Receptor Functions Are Determined by Phosphorylation. PLoS Biol., 4.","DOI":"10.1371\/journal.pbio.0040231"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2017.07.010","article-title":"B Cell Phenotypes, Signaling and Their Roles in Secretion of Antibodies in Systemic Lupus Erythematosus","volume":"186","author":"Tanaka","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and Their Receptors: Structure, Function and Signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B Cell Activating Factor) Transcript Level in Peripheral Blood of Patients with SLE Is Associated with Same-Day Disease Activity as Well as Global Activity over the next Year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF Family Members BAFF and APRIL: The Growing Complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL System in SLE Pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and Characterization of LymphoStat-B, a Human Monoclonal Antibody That Antagonizes the Bioactivities of B Lymphocyte Stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients with Systemic Lupus Erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_30","first-page":"246","article-title":"Type I Interferon Signature in Systemic Lupus Erythematosus","volume":"16","author":"Bezalel","year":"2014","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Accapezzato, D., Caccavale, R., Paroli, M.P., Gioia, C., Nguyen, B.L., Spadea, L., and Paroli, M. (2023). Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076578"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","article-title":"Functional Classification of Interferon-Stimulated Genes Identified Using Microarrays","volume":"69","author":"Holko","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of Lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tanaka, Y., Tago, F., Yamakawa, N., Aoki, M., Yagi, T., and Akira, S. (2023). A New Therapeutic Target for Systemic Lupus Erythematosus: The Current Landscape for Drug Development of a Toll-like Receptor 7\/8 Antagonist through Academia-Industry-Government Collaboration. Immunol. Med., 1\u20136.","DOI":"10.1080\/25785826.2023.2264023"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","article-title":"Beyond Pan-B-Cell-Directed Therapy\u2014New Avenues and Insights into the Pathogenesis of SLE","volume":"12","author":"Lipsky","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1172\/JCI69187","article-title":"Antigenic Liposomes Displaying CD22 Ligands Induce Antigen-Specific B Cell Apoptosis","volume":"123","author":"Macauley","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular Basis of Human CD22 Function and Therapeutic Targeting","volume":"8","author":"Sicard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-Generation Anti-CD20 Monoclonal Antibodies in Autoimmune Disease Treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar3179","article-title":"Epratuzumab Targeting of CD22 Affects Adhesion Molecule Expression and Migration of B-Cells in Systemic Lupus Erythematosus","volume":"12","author":"Daridon","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2017.01.010","article-title":"CD19, from Bench to Bedside","volume":"183","author":"Li","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/imr.12368","article-title":"Fc\u03b3RIIB and Autoimmunity","volume":"269","author":"Smith","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","article-title":"Antibody-Mediated Coengagement of Fc\u03b3RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus","volume":"186","author":"Horton","year":"2011","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10067-019-04775-z","article-title":"Increased Circulating CXCL13 Levels in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Meta-Analysis","volume":"39","author":"Bao","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Klimatcheva, E., Pandina, T., Reilly, C., Torno, S., Bussler, H., Scrivens, M., Jonason, A., Mallow, C., Doherty, M., and Paris, M. (2015). CXCL13 Antibody for the Treatment of Autoimmune Disorders. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0068-1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-020-00978-5","article-title":"T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: An Update","volume":"23","author":"Chen","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2010.01.005","article-title":"Oxidative Stress in Systemic Lupus Erythematosus: Relationship to Th1 Cytokine and Disease Activity","volume":"129","author":"Shah","year":"2010","journal-title":"Immunol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L","article-title":"Th1\/Th2 Balance of Peripheral T Helper Cells in Systemic Lupus Erythematosus","volume":"42","author":"Akahoshi","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/0891693021000008535","article-title":"Decreased IL-4 Producing CD4+ T Cells in Patients with Active Systemic Lupus Erythematosus-Relation to IL-12R Expression","volume":"35","author":"Sugimoto","year":"2002","journal-title":"AutoImmunity"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Paroli, M., Caccavale, R., Fiorillo, M.T., Spadea, L., Gumina, S., Candela, V., and Paroli, M.P. (2022). The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology. Pathogens, 11.","DOI":"10.3390\/pathogens11121547"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20651","DOI":"10.1038\/srep20651","article-title":"A Pathogenic IFN\u03b1, BLyS and IL-17 Axis in Systemic Lupus Erythematosus Patients","volume":"6","author":"Mozo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zickert, A., Amoudruz, P., Sundstr\u00f6m, Y., R\u00f6nnelid, J., Malmstr\u00f6m, V., and Gunnarsson, I. (2015). IL-17 and IL-23 in Lupus Nephritis\u2014Association to Histopathology and Response to Treatment. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0070-7"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/09612033221119455","article-title":"Elevated Apoptosis and Abnormal Apoptosis Signaling of Regulatory T Cells in Patients with Systemic Lupus Erythematosus","volume":"31","author":"Li","year":"2022","journal-title":"Lupus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1230264","DOI":"10.3389\/fimmu.2023.1230264","article-title":"Pathogenesis and Novel Therapeutics of Regulatory T Cell Subsets and Interleukin-2 Therapy in Systemic Lupus Erythematosus","volume":"14","author":"Tsai","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","article-title":"Therapeutic Potential of Targeting Tfr\/Tfh Cell Balance by Low-Dose-IL-2 in Active SLE: A Post Hoc Analysis from a Double-Blind RCT Study","volume":"23","author":"Miao","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and Safety of Low-Dose IL-2 in the Treatment of Systemic Lupus Erythematosus: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cyto.2012.07.004","article-title":"Serum Cytokine Profile in Patients with Active Lupus Nephritis","volume":"60","author":"Koenig","year":"2012","journal-title":"Cytokine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3899\/jrheum.100293","article-title":"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1\/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus","volume":"37","author":"Mok","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","article-title":"Serum Levels of IL-33 and Soluble ST2 and Their Association with Disease Activity in Systemic Lupus Erythematosus","volume":"49","author":"Mok","year":"2010","journal-title":"Rheumatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase Ii\/Iii Systemic Lupus Erythematosus Evaluation of Rituximab Trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: A Regulator of Cell-Cycle Progression of B Lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Valiullina, A.K., Zmievskaya, E.A., Ganeeva, I.A., Zhuravleva, M.N., Garanina, E.E., Rizvanov, A.A., Petukhov, A.V., and Bulatov, E.R. (2023). Evaluation of CAR-T Cells\u2019 Cytotoxicity against Modified Solid Tumor Cell Lines. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020626"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B Cell Depletion by CD19-Targeted CAR T Cells Is a Highly Effective Treatment for Murine Lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic Efficacy of Anti-CD19 CAR-T Cells in a Mouse Model of Systemic Lupus Erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/acr2.11614","article-title":"Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"5","author":"Boulougoura","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00011-021-01470-1","article-title":"Are Chimeric Antigen Receptor T Cells (CAR-T Cells) the Future in Immunotherapy for Autoimmune Diseases?","volume":"70","author":"Vasquez","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric Autoantibody Receptor T Cells Deplete NMDA Receptor-Specific B Cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1759720X2211002","DOI":"10.1177\/1759720X221100294","article-title":"Cell-Based Therapies for Rheumatoid Arthritis: Opportunities and Challenges","volume":"14","author":"Li","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T Cells Engineered with a Novel Insulin-Specific Chimeric Antigen Receptor as a Candidate Immunotherapy for Type 1 Diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"971045","DOI":"10.3389\/fimmu.2022.971045","article-title":"Neglected, yet Significant Role of FOXP1 in T-Cell Quiescence, Differentiation and Exhaustion","volume":"13","author":"Kaminskiy","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A., and Bulatov, E. (2021). Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010059"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Boroughs, A.C., Larson, R.C., Choi, B.D., Bouffard, A.A., Riley, L.S., Schiferle, E., Kulkarni, A.S., Cetrulo, C.L., Ting, D., and Blazar, B.R. (2019). Chimeric Antigen Receptor Costimulation Domains Modulate Human Regulatory T Cell Function. JCI Insight, 4.","DOI":"10.1172\/jci.insight.126194"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"M\u0171zes, G., and Sipos, F. (2023). CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option. Cells, 12.","DOI":"10.3390\/cells12111534"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of Systemic Sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered Blood B Lymphocyte Homeostasis in Systemic Sclerosis: Expanded Naive B Cells and Diminished but Activated Memory B Cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2249.1997.d01-991.x","article-title":"Circulating Levels of Soluble CD30 Are Increased in Patients with Systemic Sclerosis (SSc) and Correlate with Serological and Clinical Features of the Disease","volume":"108","author":"Giacomelli","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/1744666X.2023.2230370","article-title":"Drug Development and Novel Therapeutics to Ensure a Personalized Approach in the Treatment of Systemic Sclerosis","volume":"19","author":"Farina","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/14712598.2023.2196009","article-title":"Advances in Biological and Targeted Therapies for Systemic Sclerosis","volume":"23","author":"Low","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1038\/cti.2013.2","article-title":"Interleukin-6: A New Therapeutic Target in Systemic Sclerosis?","volume":"2","author":"Cant","year":"2013","journal-title":"Clin. Transl. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","article-title":"Specificity, Versatility, and Control of TGF-\u03b2 Family Signaling","volume":"12","author":"Derynck","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"885609","DOI":"10.3389\/fimmu.2022.885609","article-title":"The Yin and Yang of IL-17 in Systemic Sclerosis","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","article-title":"The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 Promotes Fibrosis and T Helper 2 Polarization in Systemic Sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 Interferon Activation in Systemic Sclerosis: A Biomarker, a Target or the Culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3899\/jrheum.080120","article-title":"Increased Serum Soluble OX40 in Patients with Systemic Sclerosis","volume":"35","author":"Komura","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"L925","DOI":"10.1152\/ajplung.00582.2020","article-title":"Essential Role of IL-23 in the Development of Acute Exacerbation of Pulmonary Fibrosis","volume":"321","author":"Senoo","year":"2021","journal-title":"Am. J. Physiol.-Lung. Cell. Mol. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a Patient with Severe Systemic Sclerosis (SSc) Using CD19-Targeted CAR T Cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"686155","DOI":"10.3389\/fimmu.2021.686155","article-title":"Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lin, Y.-J., Anzaghe, M., and Sch\u00fclke, S. (2020). Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9.","DOI":"10.3390\/cells9040880"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring Synovial Homeostasis in Rheumatoid Arthritis by Targeting Fibroblast-like Synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B Cell Targeted Therapies in Autoimmune Disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell\u2013Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1471-4906(02)00013-3","article-title":"IL-6: A Regulator of the Transition from Neutrophil to Monocyte Recruitment during Inflammation","volume":"24","author":"Kaplanski","year":"2003","journal-title":"Trends Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 Trans-Signalling Directly Induces RANKL on Fibroblast-like Synovial Cells and Is Involved in RANKL Induction by TNF- and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1155\/2000\/698523","article-title":"Long Term Safety of Infliximab","volume":"14","author":"Schaible","year":"2000","journal-title":"Can. J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF02274836","article-title":"Interleukin 1 Beta in Synovial Fluid Is Related to Local Disease Activity in Rheumatoid Arthritis","volume":"10","author":"Rooney","year":"1990","journal-title":"Rheumatol. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for Rheumatoid Arthritis: A Systematic Review","volume":"36","author":"Mertens","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In Vitro Elimination of Autoreactive B Cells from Rheumatoid Arthritis Patients by Universal Chimeric Antigen Receptor T Cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","article-title":"The Emergence of Universal Immune Receptor T Cell Therapy for Cancer","volume":"9","author":"Minutolo","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.autrev.2014.08.012","article-title":"Anti-Citrullinated Peptides as Autoantigens in Rheumatoid Arthritis\u2014Relevance to Treatment","volume":"13","author":"Sakkas","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus Intravenous Cyclophosphamide in Patients with Connective Tissue Disease-Associated Interstitial Lung Disease in the UK (RECITAL): A Double-Blind, Double-Dummy, Randomised, Controlled, Phase 2b Trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and Efficacy of Rituximab in Systemic Sclerosis (DESIRES): A Double-Blind, Investigator-Initiated, Randomised, Placebo-Controlled Trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/imj.15832","article-title":"Rituximab Treatment for Systemic Sclerosis-associated Interstitial Lung Disease: A Case Series of 13 Patients","volume":"53","author":"Morgan","year":"2023","journal-title":"Intern. Med. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/mr\/road040","article-title":"Role of Rituximab in the Treatment of Systemic Sclerosis: A Literature Review","volume":"33","author":"Yoshifuji","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A Moving Target in Immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","article-title":"Abatacept for the Treatment of Rheumatoid Arthritis","volume":"15","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/13543784.2016.1154943","article-title":"Abatacept for the Treatment of Systemic Lupus Erythematosus","volume":"25","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and Efficacy of Abatacept in Early Diffuse Cutaneous Systemic Sclerosis (ASSET): Open-Label Extension of a Phase 2, Double-Blind Randomised Trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-023-01125-6","article-title":"Role of IFN-\u03b1 in Rheumatoid Arthritis","volume":"26","author":"Lin","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e000286","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I Interferon Receptor Blockade with Anifrolumab Corrects Innate and Adaptive Immune Perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"996662","DOI":"10.3389\/fimmu.2022.996662","article-title":"Evaluation of Anifrolumab Safety in Systemic Lupus Erythematosus: A Meta-Analysis and Systematic Review","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042098611406318","article-title":"Immunogenicity and Other Problems Associated with the Use of Biopharmaceuticals","volume":"2","author":"Tovey","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients with Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab Monotherapy versus Adalimumab Monotherapy for Treatment of Rheumatoid Arthritis (ADACTA): A Randomised, Double-Blind, Controlled Phase 4 Trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis\u2013Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"030006052210885","DOI":"10.1177\/03000605221088558","article-title":"Tocilizumab Therapy for Persistent High-Grade Fever in Systemic Lupus Erythematosus: Two Cases and a Literature Review","volume":"50","author":"Chaoyi","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s42399-023-01543-8","article-title":"Tocilizumab Therapy for Treatment-Resistant Systemic Lupus Erythematosus with Elevated IL-6 and CRP Levels: A Case Report","volume":"5","author":"Yadav","year":"2023","journal-title":"SN Compr. Clin. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/d41573-023-00166-x","article-title":"CAR T Cell Therapies Raise Hopes\u2014And Questions\u2014For Lupus and Autoimmune Disease","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"707734","DOI":"10.3389\/fimmu.2021.707734","article-title":"Promising New Tools for Targeting P53 Mutant Cancers: Humoral and Cell-Based Immunotherapies","volume":"12","author":"Chasov","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic Antibodies: Successes, Limitations and Hopes for the Future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy","volume":"8","author":"Almagro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T Efficacy: Is Conditioning the Key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: A New Approach for the Treatment of Autoimmune Diseases","volume":"66","author":"Sun","year":"2023","journal-title":"Sci. China Life Sci."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/1\/10\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:53:00Z","timestamp":1760104380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/1\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["antib13010010"],"URL":"https:\/\/doi.org\/10.3390\/antib13010010","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}